Skip to main content

MYUNGMOON Pharm co.,Ltd (017180.KS)

Boursa KuwaitView data quality →
49.9Fair

ValueMarkers Composite Index

Top 28%#32,097 of 44,714

DCF data not available

Piotroski
4/9
Neutral
Beneish
-1.69
High Risk
Altman
0.79
Distress
DCF Value
-
N/A
ROIC
2.3%
Low
P/E
0.0
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

MYUNGMOON Pharm co.,Ltd (017180.KS) — VMCI valuation read

The headline on MYUNGMOON Pharm co.,Ltd (017180.KS) is a 50/100 VMCI score, set against a broad-market sample median of 50. That 0-point below-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value drag is in the data.

017180.KS insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** 017180.KS trades at 17.0x earnings, 6% below the sector median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the sector median (10.0%) sets the quality side. Net debt to EBITDA of -1.2x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on 017180.KS.

017180.KS rose 0.3% over the trailing 7 days, with a -17.0% read on a 30-day basis.

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, fillers, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, oral disease products, antidiarrheal agents, digestive system products, cold drugs, calcium products, nasal sprays, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.

CEO: Cheol-han Bae282 employeesKRwww.mmpharm.co.kr

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 017180.KS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.